In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants.
Adolescent
Adult
Animals
Cells, Cultured
Cellular Senescence
/ genetics
Cyclin-Dependent Kinase Inhibitor p15
/ genetics
DNA Damage
Female
Genetic Predisposition to Disease
Heterozygote
Humans
Male
Melanocytes
/ metabolism
Mutation
/ genetics
Neoplasm Proteins
/ genetics
Phosphorylation
/ radiation effects
Receptor, Melanocortin, Type 1
/ genetics
Retinoblastoma Protein
/ genetics
Ultraviolet Rays
Young Adult
beta-Galactosidase
/ metabolism
CDKN2A
MC1R
proliferation
replicative senescence
ultraviolet radiation
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
04
06
2018
revised:
03
08
2018
accepted:
09
08
2018
pubmed:
18
8
2018
medline:
9
8
2019
entrez:
18
8
2018
Statut:
ppublish
Résumé
Coinheritance of germline mutation in cyclin-dependent kinase inhibitor 2A (CDKN2A) and loss-of-function (LOF) melanocortin 1 receptor (MC1R) variants is clinically associated with exaggerated risk for melanoma. To understand the combined impact of these mutations, we established and tested primary human melanocyte cultures from different CDKN2A mutation carriers, expressing either wild-type MC1R or MC1RLOF variant(s). These cultures expressed the CDKN2A product p16 (INK4A) and functional MC1R. Except for 32ins24 mutant melanocytes, the remaining cultures showed no detectable aberrations in proliferation or capacity for replicative senescence. Additionally, the latter cultures responded normally to ultraviolet radiation (UV) by cell cycle arrest, JNK, p38, and p53 activation, hydrogen peroxide generation, and repair of DNA photoproducts. We propose that malignant transformation of melanocytes expressing CDKN2A mutation and MC1RLOF allele(s) requires acquisition of somatic mutations facilitated by MC1R genotype or aberrant microenvironment due to CDKN2A mutation in keratinocytes and fibroblasts.
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p15
0
Neoplasm Proteins
0
Receptor, Melanocortin, Type 1
0
Retinoblastoma Protein
0
beta-Galactosidase
EC 3.2.1.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
259-268Subventions
Organisme : NCI NIH HHS
ID : R21 CA183440
Pays : United States
Informations de copyright
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.